Silverarc Capital Management, LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1816307) · Explore on the interactive board
Silverarc Capital Management, LLC disclosed 65 US equity positions worth $898.5m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 13, 2026). Its largest position is ASND at 6.1% of the reported book, followed by CELC, COGT. The top ten holdings are 45.3% of the book, and the portfolio behaves like about 33 equal-weight positions. Versus the prior filing it opened 20 new positions, added to 15, reduced 27 and exited 22. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Silverarc Capital Management, LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 20 new, 15 added, 27 reduced, 22 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 6.1% | $55.0m | 206,234 | – | new |
| 2 | CELC CELCUITY INC | Healthcare | 5.8% | $52.4m | 500,996 | 40% | added |
| 3 | COGT COGENT BIOSCIENCES INC | Healthcare | 5.5% | $49.6m | 1,280,707 | -3% | reduced |
| 4 | URGN UROGEN PHARMA LTD | Healthcare | 5.3% | $47.9m | 1,301,979 | -13% | reduced |
| 5 | IMNM IMMUNOME INC | Healthcare | 4.8% | $42.7m | 2,017,009 | 9% | added |
| 6 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 4.2% | $38.0m | 390,000 | -40% | reduced |
| 7 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.8% | $34.6m | 311,461 | 2% | added |
| 8 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 3.7% | $33.6m | 352,802 | 134% | added |
| 9 | GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 3.0% | $26.8m | 1,108,295 | -45% | reduced |
| 10 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.0% | $26.5m | 1,214,390 | 37% | added |
| 11 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 2.8% | $24.8m | 489,382 | – | new |
| 12 | IMVT IMMUNOVANT INC | Healthcare | 2.7% | $23.9m | 619,096 | 49% | added |
| 13 | ERAS ERASCA INC | Healthcare | 2.6% | $23.1m | 1,263,026 | -32% | reduced |
| 14 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 2.5% | $22.6m | 2,927,698 | – | new |
| 15 | ABVX ABIVAX SA | Healthcare | 2.5% | $22.6m | 169,593 | -44% | reduced |
| 16 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 2.4% | $22.0m | 65,679 | -8% | reduced |
| 17 | KOD KODIAK SCIENCES INC | Healthcare | 2.4% | $21.3m | 546,256 | -45% | reduced |
| 18 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 2.1% | $18.8m | 400,000 | – | new |
| 19 | VCYT VERACYTE INC | Healthcare | 2.1% | $18.7m | 318,001 | 77% | added |
| 20 | GH GUARDANT HEALTH INC | Healthcare | 1.7% | $15.0m | 99,826 | 1% | added |
| 21 | CCCC C4 THERAPEUTICS INC | Healthcare | 1.6% | $14.2m | 3,032,060 | 59% | added |
| 22 | ZBIO ZENAS BIOPHARMA INC | 1.4% | $12.9m | 509,789 | -55% | reduced | |
| 23 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.4% | $12.6m | 678,095 | 33% | added |
| 24 | HELIX ACQUISITION CORP III | 1.4% | $12.5m | 1,177,821 | -3% | reduced | |
| 25 | ALXO ALX ONCOLOGY HLDGS INC | Healthcare | 1.3% | $11.9m | 5,744,757 | – | new |
| 26 | MANE VERADERMICS INC | Healthcare | 1.3% | $11.7m | 95,000 | – | new |
| 27 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.3% | $11.3m | 186,821 | -6% | reduced |
| 28 | AVALYN PHARMACEUTICALS INC | 1.2% | $10.9m | 330,487 | – | new | |
| 29 | BIIB BIOGEN INC | Healthcare | 1.2% | $10.4m | 48,101 | -6% | reduced |
| 30 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 1.1% | $10.3m | 1,946,482 | – | new |
| 31 | CERS CERUS CORP | Healthcare | 1.1% | $10.1m | 3,472,737 | 9% | added |
| 32 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.0% | $9.2m | 500,402 | – | new |
| 33 | BENITEC BIOPHARMA INC | 1.0% | $9.1m | 679,826 | -5% | reduced | |
| 34 | PCVX VAXCYTE INC | Healthcare | 0.9% | $8.4m | 145,000 | 0% | held |
| 35 | WGS GENEDX HOLDINGS CORP | Healthcare | 0.9% | $8.4m | 122,269 | – | new |
| 36 | SVRA SAVARA INC | Healthcare | 0.9% | $8.3m | 1,355,459 | -5% | reduced |
| 37 | OVID OVID THERAPEUTICS INC | Healthcare | 0.9% | $8.3m | 3,101,129 | 210% | added |
| 38 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.9% | $8.0m | 738,873 | -33% | reduced |
| 39 | CMPS COMPASS PATHWAYS PLC | Healthcare | 0.8% | $7.1m | 503,382 | 68% | added |
| 40 | CGEN COMPUGEN LTD | Healthcare | 0.8% | $6.8m | 3,184,257 | -4% | reduced |
| 41 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.7% | $6.7m | 668,450 | – | new |
| 42 | IBIO IBIO INC | 0.7% | $6.2m | 3,520,490 | 1458% | added | |
| 43 | IRON DISC MEDICINE INC | Healthcare | 0.7% | $6.1m | 82,800 | -58% | reduced |
| 44 | ALKS ALKERMES PLC | Healthcare | 0.7% | $5.9m | 113,494 | -75% | reduced |
| 45 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 0.6% | $5.3m | 59,959 | -68% | reduced |
| 46 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.6% | $5.1m | 525,000 | – | new | |
| 47 | CTNM CONTINEUM THERAPEUTICS INC | 0.5% | $4.9m | 296,135 | -2% | reduced | |
| 48 | UNIQURE NV | 0.5% | $4.8m | 105,000 | – | new | |
| 49 | RESEARCH ALLIANCE CORP III | 0.4% | $3.9m | 360,000 | – | new | |
| 50 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 0.4% | $3.8m | 610,407 | -6% | reduced |
What did Silverarc Capital Management, LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| 4XC1 KALVISTA PHARMACEUTICALS INC | 27.2% | $57.9m |
| NUVALENT INC | 17.1% | $36.4m |
| ASND ASCENDIS PHARMA A/S | 13.4% | $28.5m |
| CNTA CENTESSA PHARMACEUTICALS PLC | 8.7% | $18.5m |
| SRRK SCHOLAR ROCK HLDG CORP | 7.8% | $16.7m |
| CGON CG ONCOLOGY INC | 5.3% | $11.3m |
| CLDX CELLDEX THERAPEUTICS INC NEW | 2.7% | $5.7m |
| CYTK CYTOKINETICS INC | 2.2% | $4.7m |
| CLYM CLIMB BIO INC | 2.2% | $4.7m |
| CMPX COMPASS THERAPEUTICS INC | 2.1% | $4.5m |
| SRZN SURROZEN INC | 2.0% | $4.2m |
| ZURA ZURA BIO LTD | 1.6% | $3.3m |
| FULC FULCRUM THERAPEUTICS INC | 1.5% | $3.2m |
| ANNX ANNEXON INC | 1.3% | $2.8m |
| MNPR MONOPAR THERAPEUTICS INC | 1.1% | $2.4m |
| NXTC NEXTCURE INC | 0.9% | $1.9m |
| NMRA NEUMORA THERAPEUTICS INC. | 0.7% | $1.6m |
| EWTX EDGEWISE THERAPEUTICS INC | 0.6% | $1.3m |
| REPL REPLIMUNE GROUP INC | 0.6% | $1.3m |
| GENB GENERATE BIOMEDICINES INC | 0.6% | $1.2m |
| RADIOPHARM THERANOSTICS LTD | 0.4% | $805.8k |
| AARD AARDVARK THERAPEUTICS INC | 0.1% | $127.0k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 90.4% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Silverarc Capital Management, LLC's portfolio?
Across every quarter Silverarc Capital Management, LLC has filed, its median largest position is 6.5% of the book and its median top-ten weight is 47.1%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 21.0 completed holding spells, the median lasted 1.0 quarters; 65.0 positions are still open and their final length is unknown.